<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04127006</url>
  </required_header>
  <id_info>
    <org_study_id>Pro-EYS</org_study_id>
    <nct_id>NCT04127006</nct_id>
  </id_info>
  <brief_title>Rate of Progression in EYS Related Retinal Degeneration</brief_title>
  <acronym>Pro-EYS</acronym>
  <official_title>Rate of Progression in EYS Related Retinal Degeneration (Pro-EYS)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Jaeb Center for Health Research</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Foundation Fighting Blindness</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Jaeb Center for Health Research</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The overall goal of this project funded by the Foundation Fighting Blindness is to
      characterize the natural history of disease progression in patients with EYS mutations in
      order to accelerate the development of outcome measures for clinical trials.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This natural history study of patients with EYS mutations will accelerate the development of
      outcome measures for clinical trials. Sensitive, reliable outcome measures of retinal
      degeneration will greatly facilitate development of treatments for retinitis pigmentosa due
      to EYS mutations. Together these approaches are expected to have an impact on understanding
      EYS-related retinal degeneration, developing experimental treatment protocols, and assessing
      their effectiveness.

      The goals and expected impact of this natural history study are to:

        1. Describe the natural history of retinal degeneration in patients with biallelic
           mutations in the EYS gene

        2. Identify sensitive structural and functional outcome measures to use for future
           multicenter clinical trials in EYS-related retinal degeneration

        3. Identify well-defined subpopulations for future clinical trials of investigative
           treatments for EYS-related retinal degeneration

      Study Objectives

      The primary objectives of the natural history study are to:

        1. Characterize the natural history of retinal degeneration associated with biallelic
           pathogenic mutations in the EYS gene over 4 years, as measured using functional,
           structural, and patient-reported outcome measures

        2. Investigate whether structural outcome measures can be validated as surrogates for
           functional outcomes in individuals with biallelic pathogenic mutations in the EYS gene

        3. Evaluate possible risk factors (genotype, phenotype, environmental, and comorbidities)
           for progression of the outcome measures at 4 years in individual with biallelic
           pathogenic mutations in the EYS gene

        4. Evaluate variability and symmetry of left and right eye outcomes over 4 years in
           individuals with biallelic pathogenic mutations in the EYS gene
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">February 25, 2020</start_date>
  <completion_date type="Anticipated">January 2024</completion_date>
  <primary_completion_date type="Anticipated">January 2024</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Visual Field Sensitivity</measure>
    <time_frame>Baseline and every year until study completion (4 years)</time_frame>
    <description>Measured by static perimetry with topographic analysis (Hill of Vision) and assessed by a central reading center for cohorts 1 and 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Best Corrected Visual Acuity</measure>
    <time_frame>Screening visit and every year until study completion (4 years) with the exception of baseline for cohorts 1 and 2. Screening visit and 48 month follow-up for cohort 3.</time_frame>
    <description>Measured on the Electronic Visual Acuity (EVA) system or ETDRS charts. Berkeley Rudimentary Vision Test (BRVT) will be used for patients unable to see letters.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Mean Retinal Sensitivity</measure>
    <time_frame>Baseline and every year until study completion (4 years).</time_frame>
    <description>Measured by fundus-guided microperimetry (MP) and assessed by a central reading center at selected sites with requisite equipment for cohorts 1 and 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Full-field Retinal Sensitivity</measure>
    <time_frame>Baseline and every year until study completion (4 years) for cohort 1 and 2. Baseline and 4 year follow-up for cohort 3.</time_frame>
    <description>Measured by full-field stimulus threshold (FST) testing to blue, white, and red stimuli</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Best Corrected Low Luminance visual acuity</measure>
    <time_frame>Screening visit and every year until study completion (4 years) with the exception of baseline for cohorts 1 and 2. Screening visit and 48 month follow-up for cohort 3.</time_frame>
    <description>Measured by letter score</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Contrast Sensitivity Function</measure>
    <time_frame>Baseline and every year until study completion (4 years).</time_frame>
    <description>Measured by the CSV-1000E VectorVision chart for cohorts 1 and 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Retinal Function</measure>
    <time_frame>Baseline and 4 year follow-up visit.</time_frame>
    <description>Measured by full-field electroretinogram (ERG) amplitudes and timing in response to rod- and cone-specific stimuli for cohorts 1 and 2.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Change in Ellipsoid zone (EZ) area</measure>
    <time_frame>Baseline and every year until study completion (4 years) for cohorts 1 and 2. Baseline and 4 year follow-up for cohort 3.</time_frame>
    <description>Measured by spectral domain optical coherence tomography (SD-OCT) and assessed by a central reading center</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Explore Qualitative categorization of Fundus Autofluorescence (FAF) pattern</measure>
    <time_frame>Baseline and every year until study completion (4 years) for cohorts 1 and 2. Baseline and 4 year follow-up for cohort 3.</time_frame>
    <description>Assessed by a central reading center</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Explore quantitative measures of FAF</measure>
    <time_frame>Baseline and every year until study completion (4 years) for cohorts 1 and 2. Baseline and 4 year follow-up for cohort 3.</time_frame>
    <description>assessed by a central reading center</description>
  </secondary_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes for Vision Cohorts 1 and 2 (Vision Visual Functioning)</measure>
    <time_frame>Baseline, 2 year follow-up, and 4 year follow-up visit</time_frame>
    <description>Measured by Veterans Affairs Low Vision Visual Functioning Questionnaire (VA LV VFQ-48)</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes for Vision Cohorts 1 and 2</measure>
    <time_frame>Baseline, 2 year follow-up, and 4 year follow-up visit</time_frame>
    <description>Measured by Patient-Reported Outcomes Measurement Information System (PROMIS®-29)</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes for Vision Cohort 3 (Vision Visual Functioning)</measure>
    <time_frame>Baseline and 4 year follow-up visit</time_frame>
    <description>Measured by Ultra-Low Vision Visual Functioning Questionnaire (ULV-VFQ-50)</description>
  </other_outcome>
  <other_outcome>
    <measure>Patient Reported Outcomes for Vision Cohort 3</measure>
    <time_frame>Baseline and 4 year follow-up visit</time_frame>
    <description>Measured by Patient-Reported Outcomes Measurement Information System (PROMIS®-29)</description>
  </other_outcome>
  <number_of_groups>3</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Retinitis Pigmentosa</condition>
  <condition>Eye Diseases</condition>
  <arm_group>
    <arm_group_label>Vision Cohort 1</arm_group_label>
    <description>Participants with the better eye Screening Visit visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter 10 degrees or more in every meridian of the central field</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vision Cohort 2</arm_group_label>
    <description>Participants with the better eye Screening Visit visual acuity ETDRS letter score of 19-53 [approximate Snellen equivalent 20/100 - 20/400] or (visual acuity ETDRS letter score of 54 or more [approximate Snellen equivalent 20/80 or better] and visual field diameter less than 10 degrees in any meridian of the central field)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Vision Cohort 3</arm_group_label>
    <description>Participants with the better eye Screening Visit visual acuity ETDRS letter score of 18 or less [approximate Snellen equivalent 20/500 or worse]</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Saliva samples
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        Potential eligibility may be assessed as part of a routine care examination by an
        investigator prior to obtaining informed consent, as part of usual care, by referral from
        another physician, or self-referral.
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Willing to participate in the study and able to communicate consent during the consent
             process

          2. Ability to return for all study visits over 48 months

          3. Age ≥ 18 years

          4. Must meet one of the Genetic Screening Criteria, defined below:

               -  Screening Group A: At least 2 disease-causing variants in the EYS gene which are
                  homozygous or heterozygous in trans, based on a report from a
                  clinically-certified lab (or a report from a research lab that has been pre-
                  approved by the Genetics Committee)

               -  Screening Group B: Only 1 disease-causing variant in the EYS gene, based on a
                  report from a clinically-certified lab (or a report from a research lab which has
                  been pre-approved by the Genetics Committee)

               -  Screening Group C: At least 2 disease-causing variants in the EYS gene which are
                  unknown phase, based on a report from a clinically-certified lab (or a report
                  from a research lab which has been pre-approved by the Genetics Committee)

        Note pertaining to all Screening Groups: if a participant has a variant(s) of unknown
        significance, he/she would still qualify as long as there is at least 1 disease-causing
        variant(s) on the EYS gene.

        Ocular Inclusion Criteria:

        Both eyes must meet all of the following:

          1. Clinical diagnosis of retinal dystrophy

          2. Clear ocular media and adequate pupil dilation to permit good quality photographic
             imaging

        Exclusion Criteria:

          1. Mutations in genes that cause autosomal dominant retinitis pigmentosa (ADRP), X-linked
             retinitis pigmentosa (RP), or presence of biallelic mutations in autosomal recessive
             RP/retinal dystrophy genes other than EYS

          2. Expected to enter experimental treatment trial at any time during this study

          3. History of more than 1 year of cumulative treatment, at any time, with an agent
             associated with pigmentary retinopathy (including hydroxychloroquine, chloroquine,
             thioridazine, and deferoxamine)

        Ocular exclusion Criteria:

        If either eye has any of the following, the participant is not eligible:

          1. Current vitreous hemorrhage

          2. Current or any history of rhegmatogenous retinal detachment

          3. Current or any history of (e.g., prior to cataract or refractive surgery) spherical
             equivalent of the refractive error worse than -8 Diopters of myopia

          4. History of intraocular surgery (e.g., cataract surgery, vitrectomy, penetrating
             keratoplasty, or LASIK) within the last 3 months

          5. Current or any history of confirmed diagnosis of glaucoma (e.g., based on glaucomatous
             VF changes or nerve changes, or history of glaucoma filtering surgery)

          6. Current or any history of retinal vascular occlusion or proliferative diabetic
             retinopathy

          7. History or current evidence of ocular disease that, in the opinion of the
             investigator, may confound assessment of visual function

          8. History or evidence of active treatment for retinitis pigmentosa that could affect the
             progression of retinal degeneration, including:

               1. Any use of ocular stem cell or gene therapy

               2. Any treatment with ocriplasmin

               3. Treatment with an ophthalmic oligonucleotide within the last 9 months (last
                  treatment date is less than 9 months prior to Screening Visit date)

               4. Treatment with any other product within five times the expected half-life of the
                  product (time from last treatment date to Screening Visit date is at least 5
                  times the half-life of the given product)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Mark Pennesi, MD, PhD</last_name>
    <role>Study Chair</role>
    <affiliation>Division Chief, Ophthalmic Genetics Oregon Health &amp; Science University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Coordinating Center</last_name>
    <phone>813-975-8690</phone>
    <email>ffb@jaeb.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Associated Retina Consultants</name>
      <address>
        <city>Phoenix</city>
        <state>Arizona</state>
        <zip>85020</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Benjamin Bakall, M.D.,Ph.D</last_name>
      <phone>602-242-4928</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California-San Diego: Shirley Eye Institute</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92093</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Daniel L Chao, M.D.,Ph.D</last_name>
      <phone>858-534-6290</phone>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of California, San Francisco</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94143-0344</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jacque Duncan, M.D.</last_name>
      <email>jacque.duncan@ucsf.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Colorado Retina Associates</name>
      <address>
        <city>Denver</city>
        <state>Colorado</state>
        <zip>80230</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alan Kimura, M.D., M.P.H</last_name>
      <phone>303-261-1600</phone>
      <email>akimura@retinacolorado.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>National Eye Institute (NEI)</name>
      <address>
        <city>Washington</city>
        <state>District of Columbia</state>
        <zip>20892</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Catherine Cukras, M.D.,Ph.D</last_name>
      <phone>301-496-6583</phone>
      <email>cukrasc@nei.nih.gov</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Vitreo-Retinal Associates</name>
      <address>
        <city>Gainesville</city>
        <state>Florida</state>
        <zip>32607</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Christine Kay, M.D.</last_name>
      <email>christinenkay@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Miami: Neuro-ophthalmology Department</name>
      <address>
        <city>Miami</city>
        <state>Florida</state>
        <zip>33136</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bryon Lam, M.D.</last_name>
      <phone>305-326-6000</phone>
      <email>blam@miami.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Emory Eye Center</name>
      <address>
        <city>Atlanta</city>
        <state>Georgia</state>
        <zip>30322</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Nieraj Jain, M.D.</last_name>
      <phone>404-778-2020</phone>
    </contact>
    <contact_backup>
      <email>nieraj.jain@emory.edu</email>
    </contact_backup>
  </location>
  <location>
    <facility>
      <name>University of Kentucky</name>
      <address>
        <city>Lexington</city>
        <state>Kentucky</state>
        <zip>40508</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ramiro S. Maldonado, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Wilmer Eye Institute at Johns Hopkins</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21287-9277</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Mandeep Singh, M.D.</last_name>
      <email>msingh27@jhmi.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Massachusetts Eye and Ear</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02114</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Rachel Huckfeldt, M.D.</last_name>
      <email>rachel_huckfeldt@meei.harvard.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kellogg Eye Center, University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48105</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Thiran Jayasundera, M.D.</last_name>
      <email>thiran@umich.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Duke University Eye Center</name>
      <address>
        <city>Durham</city>
        <state>North Carolina</state>
        <zip>27710</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Alessandro Iannaccone, M.D.</last_name>
      <email>alessandro.iannaccone@duke.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Oregon Health Science University Casey Eye Institute</name>
      <address>
        <city>Portland</city>
        <state>Oregon</state>
        <zip>97239</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Pennesi, M.D., Ph.D</last_name>
      <email>pennesim@ohsu.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Pittsburgh School of Medicine: Department of Ophthalmology</name>
      <address>
        <city>Pittsburgh</city>
        <state>Pennsylvania</state>
        <zip>15213</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose-Alain Sahel, M.D.</last_name>
      <phone>412-647-3555</phone>
      <email>j.sahel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Retina Foundation of the Southwest</name>
      <address>
        <city>Dallas</city>
        <state>Texas</state>
        <zip>75231</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>David Birch, Ph.D</last_name>
      <email>dbirch@retinafoundation.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Wisconsin-Madison: McPherson Eye Research Institute</name>
      <address>
        <city>Madison</city>
        <state>Wisconsin</state>
        <zip>53705</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Kimberly Stepien, M.D.</last_name>
      <phone>608-263-9338</phone>
      <email>kstepien@wisc.edu</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Ghent University Hospital: Department of Ophthalmology</name>
      <address>
        <city>Gent</city>
        <zip>9000</zip>
        <country>Belgium</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Bart P. Leroy, M.D.,Ph.D</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Federal University of São Paulo</name>
      <address>
        <city>São Paulo</city>
        <zip>04021-001</zip>
        <country>Brazil</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Juliana M. Sallum, M.D.</last_name>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital for Sick Children</name>
      <address>
        <city>Toronto</city>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elise Heon, M.D.</last_name>
      <email>elise.heon@sickkids.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centre hospitalier National d'Ophtalmologie des Quinze-Vingts</name>
      <address>
        <city>Paris</city>
        <zip>75012</zip>
        <country>France</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Jose Alain-Sahel, M.D.</last_name>
      <email>j.sahel@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Tubingen</name>
      <address>
        <city>Tübingen</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Katarina Stingl, M.D.</last_name>
      <email>Katarina.Stingl@med.uni-tuebingen.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hadassah Medical Center</name>
      <address>
        <city>Jerusalem</city>
        <country>Israel</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Eyal Banin, M.D.,Ph.D</last_name>
      <phone>02-6776585</phone>
      <email>Banin@Hadassah.org.il</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Radboud University</name>
      <address>
        <city>Nijmegen</city>
        <country>Netherlands</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Carel Hoyng, M.D.</last_name>
      <email>Carel.Hoyng@radboudumc.nl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medical University of Lublin: Department of Ophthalmology</name>
      <address>
        <city>Lublin</city>
        <zip>20-059</zip>
        <country>Poland</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Robert Rejdak, M.D., Ph.D</last_name>
      <phone>0048 81 532 61 49</phone>
      <email>robertrejdak@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moorfields Eye Hostpital</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <contact>
      <last_name>Michel Michaelides, M.D.</last_name>
      <email>michel.michaelides@ucl.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Belgium</country>
    <country>Brazil</country>
    <country>Canada</country>
    <country>France</country>
    <country>Germany</country>
    <country>Israel</country>
    <country>Netherlands</country>
    <country>Poland</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://public.jaeb.org/ffb</url>
    <description>Foundation Fighting Blindness Public Website</description>
  </link>
  <verification_date>June 2020</verification_date>
  <study_first_submitted>October 11, 2019</study_first_submitted>
  <study_first_submitted_qc>October 11, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">October 15, 2019</study_first_posted>
  <last_update_submitted>June 29, 2020</last_update_submitted>
  <last_update_submitted_qc>June 29, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">June 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>EYS mutation</keyword>
  <keyword>Retinitis Pigmentosa</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Retinitis</mesh_term>
    <mesh_term>Retinitis Pigmentosa</mesh_term>
    <mesh_term>Retinal Degeneration</mesh_term>
    <mesh_term>Eye Diseases</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>A de-identified database is placed in the public domain on the FFB/Jaeb public website after the completion of each protocol and publication of the manuscript.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Informed Consent Form (ICF)</ipd_info_type>
    <ipd_time_frame>After manuscript is published</ipd_time_frame>
    <ipd_access_criteria>Users accessing data must enter an email address</ipd_access_criteria>
  </patient_data>
  <provided_document_section>
    <provided_document>
      <document_type>Study Protocol</document_type>
      <document_has_protocol>Yes</document_has_protocol>
      <document_has_icf>No</document_has_icf>
      <document_has_sap>No</document_has_sap>
      <document_date>September 11, 2019</document_date>
      <document_url>https://ClinicalTrials.gov/ProvidedDocs/06/NCT04127006/Prot_000.pdf</document_url>
    </provided_document>
  </provided_document_section>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

